All In Biotech

Drug Trial Radar · NCT02860000

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

MC1431 Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

96

Actual

Start

Jul 6, 2017

Primary completion

Jan 10, 2022

Study completion Feb 14, 2025

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Aug 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer.

Conditions

  • Estrogen Receptor Status
  • HER2/Neu Negative
  • Invasive Breast Carcinoma
  • Postmenopausal
  • Stage III Breast Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIB Breast Cancer
  • Stage IIIC Breast Cancer
  • Stage IV Breast Cancer

Interventions

  • AlisertibDrug

    Given PO

  • FulvestrantDrug

    Given IM

  • Laboratory Biomarker AnalysisOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tumor Response Rate Defined as 100% Times the Number of Patients Who Meet the Criteria for Complete Response (CR) or Partial Response (PR) Using RECIST Criteria Version 1.1Time frame: Up to 4.5 years

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Montefiore Medical Center

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Vanderbilt Breast Center at One Hundred Oaks

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.